Crestor vs Losartan: Which Drug Actually Does More for Your Heart Health?

The Core Difference: These Two Drugs Are Not Competing

Rosuvastatin and losartan are rarely a true either/or choice for women. They address distinct physiological problems and are prescribed for different indications. Comparing them head-to-head is a bit like comparing metformin to lisinopril: both are cardiometabolic drugs, but they act on completely separate pathways.

No randomized controlled trial has ever placed rosuvastatin directly against losartan to test which reduces cardiovascular events more, because doing so would be clinically meaningless. What does exist is strong individual trial data for each drug, some sex-stratified analyses, and real-world prescribing patterns that show many women end up on both.

What Rosuvastatin Actually Does

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. This lowers circulating LDL-C, raises HDL-C modestly, and reduces triglycerides. It also has pleiotropic anti-inflammatory effects: the JUPITER trial showed that rosuvastatin 20 mg reduced hsCRP (high-sensitivity C-reactive protein) by 37% alongside a 50% reduction in LDL-C, driving a 44% reduction in major adverse cardiovascular events in adults who had normal LDL but elevated hsCRP at baseline.

What Losartan Actually Does

Losartan blocks the AT1 receptor for angiotensin II, causing systemic vasodilation and lower blood pressure. It also reduces aldosterone secretion, has mild uricosuric properties (useful in women with gout), and independently slows progression of diabetic kidney disease. The LIFE trial demonstrated a 13% reduction in the composite primary endpoint of cardiovascular death, stroke, and myocardial infarction compared with atenolol in patients with hypertension and left ventricular hypertrophy, with particularly strong stroke reduction.

How Each Drug Performs in Women Specifically

Women have been under-represented in major cardiovascular trials for decades. Sex-stratified data exists but is often from subgroup analyses, not pre-specified primary endpoints. This matters when you are reading any efficacy claim.

Rosuvastatin: What the Women's Data Shows

The JUPITER trial enrolled 6,801 women out of 17,802 total participants, making it one of the larger sex-inclusive statin trials. In women, rosuvastatin reduced the primary endpoint by approximately 46%, slightly higher than the overall 44% result, though the confidence intervals overlapped. The signal was consistent.

Women tend to present with cardiovascular disease later in life than men, often in the postmenopausal decade. After menopause, estrogen withdrawal accelerates LDL-C rise, increases small dense LDL particles, and raises lipoprotein(a). The American College of Cardiology and American Heart Association 2019 guideline recommends statin therapy for women with 10-year ASCVD risk at or above 7.5%, using the Pooled Cohort Equations.

Women also have sex-specific statin risks. The absolute risk of statin-associated muscle symptoms (SAMS) is modestly higher in women, and observational data suggests women may be more likely to discontinue statins due to myalgia. Starting rosuvastatin at 5 mg rather than 10 mg or 20 mg is a reasonable approach in smaller-framed or older women before titrating up. Women of East Asian descent have higher plasma rosuvastatin concentrations at equivalent doses due to pharmacokinetic differences, and the FDA label recommends starting at 5 mg in this population.

Losartan: What the Women's Data Shows

The LIFE trial enrolled 4,963 women out of 9,193 total participants. Women in LIFE had consistent benefit from losartan over atenolol for stroke reduction, which is the endpoint where losartan's advantage over beta-blockers is most pronounced. This matters because stroke risk in women is shaped differently than in men: women have higher lifetime stroke risk, atrial fibrillation is a stronger stroke risk factor in women, and hypertension becomes more prevalent in women than in men after age 65.

Women also tend to respond similarly to men in terms of blood pressure lowering on ARBs, but some pharmacokinetic data shows that women have slightly higher ARB plasma concentrations at equivalent doses, possibly due to differences in renal clearance and body composition. ACE inhibitor cough, a common reason to switch to an ARB, is two to three times more common in women than in men. If you were switched from an ACE inhibitor (lisinopril, enalapril) to losartan because of cough, that is a very common and appropriate path.

Life-Stage Guide: Which Drug, at What Point in a Woman's Life

This framework does not exist in a single published guideline. It synthesizes current ACC/AHA, ACOG, and JNC8-equivalent guidance into a life-stage decision structure specifically for women.

Reproductive Years (Ages 18-40)

Hypertension at this life stage is less common but not rare. Secondary causes including renal artery stenosis, PCOS-related insulin resistance, and hormonal contraceptive use account for a higher proportion of hypertension in young women than in older women.

For a woman in her 20s or 30s with hypertension and no compelling indication, ACOG recommends calcium channel blockers or thiazide diuretics as first-line agents for most women of reproductive potential, precisely because ARBs like losartan are fetotoxic. If a woman is on losartan at this life stage, she must use reliable contraception.

Statins at this age are prescribed mainly for familial hypercholesterolemia (FH). FH affects approximately 1 in 250 people in the general population, and women with FH carry significant premature CVD risk. Rosuvastatin is effective and potent, but it is absolutely contraindicated in pregnancy.

Trying to Conceive

Both drugs must be stopped before attempting pregnancy. Full stop. See the pregnancy section below.

PCOS

Women with PCOS have a two to three times higher prevalence of hypertension and significantly elevated LDL-C and triglycerides compared with age-matched controls. A 2018 systematic review found that statins reduced testosterone levels and improved lipid profiles in PCOS, suggesting a dual benefit. Rosuvastatin specifically has been studied in small PCOS trials and shows favorable effects on androgen excess and lipids, though large RCTs are still lacking.

Losartan has no specific indication in PCOS, but women with PCOS and concurrent hypertension or early diabetic nephropathy may benefit.

Perimenopause (Ages 40-55, Variable)

Perimenopause is a critical window for cardiometabolic risk escalation in women. LDL-C rises by approximately 10-15 mg/dL across the menopause transition, driven by falling estrogen. Blood pressure also tends to rise. This is the life stage where many women first qualify for statin therapy or see their blood pressure cross the 130/80 mm Hg threshold that the 2017 ACC/AHA hypertension guideline defines as stage 1 hypertension.

For a perimenopausal woman with LDL-C above 190 mg/dL or a 10-year ASCVD risk above 7.5%, rosuvastatin is a standard intervention. For a perimenopausal woman with blood pressure consistently above 130/80 and target organ involvement or diabetes, losartan is a rational first-line choice.

Postmenopause

This is where both drugs are most commonly used together. Postmenopausal women carry the highest absolute cardiovascular risk in the female population. An LDL goal below 70 mg/dL is appropriate for women with established ASCVD, and high-intensity statin therapy with rosuvastatin 20-40 mg is a standard approach to reach that goal. Concurrent blood pressure management with an ARB is extremely common.

Pregnancy and Lactation: Both Drugs Are Contraindicated

This section is non-negotiable reading if you are of reproductive age and on either of these medications.

Rosuvastatin in Pregnancy

Rosuvastatin is contraindicated in pregnancy. The FDA labeling assigns it a Pregnancy Category X designation, meaning the risks to a developing fetus outweigh any possible benefit. Animal studies showed skeletal malformations at doses lower than the human therapeutic range. Human data is limited and largely from inadvertent exposures, which have not conclusively demonstrated teratogenicity, but the theoretical mechanism (cholesterol is essential for fetal development) justifies absolute contraindication.

Rosuvastatin should be stopped at least 4 weeks before attempting conception, though some clinicians advise longer washout given the drug's half-life of approximately 19 hours and its tissue distribution.

Lactation: Rosuvastatin is present in breast milk in animal studies. Because of the potential for serious adverse effects in a nursing infant, rosuvastatin is not recommended during breastfeeding.

Losartan in Pregnancy

Losartan is contraindicated in pregnancy, particularly from the second trimester onward. Fetal exposure to angiotensin II receptor blockers causes fetal renal tubular dysplasia, neonatal renal failure, oligohydramnios, skull hypoplasia, limb contractures, and intrauterine death. First-trimester exposure carries lower but still meaningful risk.

If a woman becomes pregnant while on losartan, the drug should be discontinued immediately. Her clinician will typically transition her to methyldopa, labetalol, or a calcium channel blocker, which are the agents with the best safety data in pregnancy.

Lactation: It is unknown whether losartan is excreted in human breast milk. Because of potential neonatal effects on blood pressure and kidney function, losartan is generally not recommended during breastfeeding.

Contraception Requirement

Any woman of reproductive potential prescribed either rosuvastatin or losartan should be using reliable contraception and have a clear plan for discontinuation before attempting pregnancy. This conversation should happen at the time of prescribing, not after a positive pregnancy test.

Dosing and Pharmacology: A Side-by-Side Look

| Feature | Rosuvastatin (Crestor) | Losartan | |---|---|---| | Drug class | HMG-CoA reductase inhibitor | Angiotensin II receptor blocker (ARB) | | Available doses | 5, 10, 20, 40 mg | 25, 50, 100 mg | | Typical starting dose | 10-20 mg once daily | 50 mg once daily | | Women-specific starting note | 5 mg in East Asian women or small-framed older women | Standard; monitor BP response | | Half-life | ~19 hours | ~2 hours (active metabolite ~6-9 hours) | | Renal dosing | 5 mg max if eGFR <30 | No dose adjustment required; used to protect kidneys | | Pregnancy | Contraindicated | Contraindicated | | Lactation | Not recommended | Not recommended | | Primary outcome target | LDL-C, hsCRP, ASCVD risk | Blood pressure, proteinuria, stroke |

Common Conditions Where Both Drugs May Be Prescribed Together

Metabolic Syndrome in Perimenopausal Women

Metabolic syndrome in women is defined by the same ATP III criteria as in men (abdominal obesity, high triglycerides, low HDL, elevated fasting glucose, elevated blood pressure), but its prevalence in women surges at menopause. A perimenopausal woman with metabolic syndrome may simultaneously have LDL-C above her target and blood pressure above 130/80 mm Hg. That is a woman who may need rosuvastatin for her cholesterol and losartan for her pressure. The drugs do not interact in any clinically meaningful way.

Type 2 Diabetes with Hypertension

Women with type 2 diabetes who also have hypertension are strong candidates for both drug classes. ARBs are preferred over other antihypertensives in diabetic women because of renal protection. The ADA Standards of Care 2024 recommend ACE inhibitors or ARBs as preferred in diabetes with hypertension and albuminuria. Simultaneously, women with diabetes over age 40 with any additional ASCVD risk factor qualify for moderate to high-intensity statin therapy.

Cardiovascular Disease Prevention After 55

Postmenopausal women with established atherosclerotic cardiovascular disease (ASCVD) typically require high-intensity statin therapy. Rosuvastatin 20-40 mg is one of only two statins (alongside atorvastatin 40-80 mg) classified as high-intensity by the ACC/AHA guidelines. If this same woman has hypertension, losartan or another ARB is layered on top.

Side Effects and Monitoring: What to Watch for as a Woman

Rosuvastatin Side Effects Relevant to Women

Muscle symptoms are the most common reason women stop statins. The SAMSON trial, a crossover N-of-1 design, found that approximately 90% of muscle symptoms on statins were not pharmacologically attributable to the drug in blinded conditions, but the nocebo effect is real and women experience it more than men. A CK level and thyroid function check (hypothyroidism amplifies statin-related myopathy) should be part of baseline workup.

Rosuvastatin increases fasting glucose modestly. A meta-analysis showed statins increase new-onset diabetes risk by approximately 9% overall, with higher risk at high intensity doses. For postmenopausal women, who are already at elevated diabetes risk, this merits monitoring with a periodic HbA1c.

Losartan Side Effects Relevant to Women

Losartan is generally well tolerated. It does not cause the dry cough that ACE inhibitors produce. Hyperkalemia is the most clinically significant risk, particularly in women with chronic kidney disease or diabetes. Dizziness and lightheadedness on first dose are more common in volume-depleted women (for example, those on diuretics or with poor oral intake).

Losartan slightly raises serum creatinine in the first weeks of treatment. A modest rise (10-20%) is expected and acceptable. A sharp rise above 30% suggests possible bilateral renal artery stenosis and warrants urgent review.

Who This Is Right For (and Who It Is Not)

Rosuvastatin is likely right for you if:

• Your LDL-C is above your personalized target and lifestyle change alone has not reached goal
• Your 10-year ASCVD risk is 7.5% or above
• You have elevated hsCRP (above 2 mg/L) with normal LDL, as in the JUPITER population
• You have familial hypercholesterolemia at any age
• You are postmenopausal with any additional risk factor (smoking, hypertension, diabetes, family history)
• You have PCOS with significant dyslipidemia

Rosuvastatin is not right for you if:

• You are pregnant or planning pregnancy in the near term
• You are breastfeeding
• You have active liver disease or persistently elevated transaminases
• You are currently taking cyclosporine (where dose is capped at 5 mg due to drug interaction)

Losartan is likely right for you if:

• Your blood pressure is consistently above 130/80 mm Hg and lifestyle modification has not reached goal
• You have diabetes with hypertension and microalbuminuria or proteinuria
• You were switched from an ACE inhibitor because of cough
• You have hypertension and left ventricular hypertrophy (the LIFE trial population)
• You have chronic kidney disease and need renoprotective antihypertensive therapy

Losartan is not right for you if:

• You are pregnant or planning pregnancy
• You are breastfeeding
• Your potassium is above 5.0 mEq/L at baseline without a clear reason to manage it
• You are also taking aliskiren if you have diabetes or renal impairment (contraindicated combination)
• Your blood pressure problem is primarily due to high LDL or inflammation, not elevated vascular resistance

Can You Switch From One to the Other?

Women sometimes ask whether they can swap rosuvastatin for losartan or vice versa. The short answer: no, not as a like-for-like substitution. They treat different conditions. A switch from rosuvastatin to losartan would leave high LDL-C completely untreated. A switch from losartan to rosuvastatin would leave elevated blood pressure completely untreated.

The situations where a genuine drug-to-drug change makes sense are:

1. Switching from one statin to another (for example, atorvastatin to rosuvastatin for greater LDL lowering).
2. Switching from one ARB to another (for example, valsartan to losartan for cost or tolerability).
3. Switching from an ACE inhibitor to losartan specifically because of cough, which is a women-heavy reason given that cough occurs in up to 20% of women on ACE inhibitors.

If you have been told to "switch" from Crestor to losartan by a non-prescribing source, that recommendation almost certainly reflects a misunderstanding of what each drug does. Bring it to your clinician with the specific concern that led to the suggestion.

A Note on Evidence Gaps for Women

Women were historically under-represented in cardiovascular outcome trials. JUPITER enrolled 38% women, which is better than many older trials but still not proportionate. The LIFE trial enrolled 54% women, making it one of the better-powered sex-inclusive hypertension trials of its era.

What we do not have is dedicated trial data on:

• Rosuvastatin efficacy and dosing in perimenopausal women specifically, where hormonal flux changes lipid metabolism from month to month
• Losartan versus other ARBs in women with PCOS-related hypertension
• Long-term outcomes for women who start either drug in the late reproductive years versus postmenopause

The sex-stratified subgroup data that does exist is reassuring and generally consistent with the overall trial results, but women deserve primary endpoint trials powered for sex-specific conclusions. Until those exist, extrapolation from mixed-sex trial data is the standard of care, and your clinician should be transparent about that.